Alteogen Signs License Agreement for Clinical Trials and Sales of Biopharmaceutical Candidate ALT-L9
[Asia Economy Reporter Oh Ju-yeon] Alteogen announced on the 10th that it has signed a license agreement with Altos Biologics Co., Ltd. for the clinical trials and sales of the biopharmaceutical candidate ALT-L9.
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- "Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- "We're Now Earning 10 Million Won a Month"... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- Experts Are Already Watching Closely..."Target Stock Price 970,000 Won" Now Only the Uptrend Remains [Weekend Money]
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
